Loading clinical trials...

A Trial of HRS-1893 in Healthy Volunteers | Clinical Trials | Clareo Health

COMPLETEDEARLY_PHASE1

A Trial of HRS-1893 in Healthy Volunteers

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of HRS-1893 in Healthy Participants

NCT07033455•Atridia Pty Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Healthy white participants;
•2. Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study.
•3. Male aged between 18 to 55 years of age (inclusive)
•4. Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 30.0 kg/m2 (inclusive) at screening.
•5. Negative pregnancy test for women of childbearing potential (WOCBP) at baseline. Men and WOCBP must agree to take highly effective contraceptive methods

Exclusion Criteria

•1. History or evidence of clinically significant disorders
•2. History of cardiomyopathy and/or unexplained heart failure
•3. Individuals with a history of drug allergies, specific allergies
•4. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.

Locations (1)

Linear Clinical Research

Nedlands, Western Australia, Australia

Key Dates

Start Date

June 25, 2025

Primary Completion Date

September 5, 2025

Completion Date

October 30, 2025

Last Updated

November 18, 2025

Enrollment

ACTUAL participants

Conditions

Hypertrophic Cardiomyopathy

Interventions

HRS-1893

DRUG

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259

Hypertrophic Cardiomyopathy

View study

RECRUITING

HCMR Re-Imaging Study

NCT07054073

Hypertrophic Cardiomyopathy (HCM)

View study

RECRUITING

Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)

NCT07344480

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Trial of HRS-1893 in Healthy Volunteers

Inclusion Criteria

Exclusion Criteria

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

HCMR Re-Imaging Study

Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)

Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes

Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy

Multimodal Analysis of Endomyocardial Biopsies